Monoclonal antibody 323A3

Drug Profile

Monoclonal antibody 323A3

Alternative Names: 323A3; Monoclonal antibody 323-A3

Latest Information Update: 18 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Developer Centocor; Nonindustrial source
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Cancer

Most Recent Events

  • 18 May 2010 Discontinued - Phase-I for Breast cancer in USA (unspecified route)
  • 18 May 2010 Discontinued - Preclinical for Cancer in Netherlands (unspecified route)
  • 18 Oct 1999 Centocor is now a wholly owned subsidiary of Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top